News

If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your ...
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...
Jonathan D. Grinstein, PhD, Manfred Scholz, PhD, and Erik Wiklund, PhD, go behind the headlines to address a shifting policy landscape and what it means for the future of chronic disease, diagnostics, ...
Wall Street halted a rally that drove stocks to the brink of a record amid concerns about an overheated market. Treasuries ...
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...
Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday.